10X Genomics Reports Q2 Preliminary Revenues, Shares Plummet On Missing Street Expectation

• 10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenue is expected to be ~$114.5 million, a decrease of 1% year-over-year, below the consensus of $127.7 million.

• The company sees America's revenue of ~$70.9 million (+8% Y/Y), EMEA ~$25.6 million (-11% Y/Y), and APAC of ~$18.1 million (-15% Y/Y).

• Separately, 10x Genomics announced the appointment of Jim Wilbur, Ph.D., as Chief Commercial Officer, effective July 27.

• Mr. Wilbur brings nearly 30 years of experience building businesses, developing high-performance teams, and scaling commercial organizations to drive growth and customer success. He joins 10x Genomics from Meso Scale Discovery (MSD), the world's leading provider of highly sensitive multiplex immunoassays.

• Earlier today, Goldman Sachs lowered the price target on 10X Genomics to $60 (an upside of 38.6%) from $80 while maintaining the Neutral rating on the shares.

• Price Action: TXG shares are trading lower by 14.55% at $36.99 during the post-market session on Thursday.

Latest Ratings for TXG

Date	Firm	Action	From	To
Feb 2022	Citigroup	Maintains		Buy
Nov 2021	Morgan Stanley	Maintains		Overweight
Sep 2021	National Bank Of Canada	Initiates Coverage On		Sector Perform

View More Analyst Ratings for TXG

View the Latest Analyst Ratings

See more from Benzinga

• American Outdoor Brands Stock Slips After Q4 Results, Clocks ~29% Sales Decline

• Deutsche Bank Cuts Delta Air Lines Price Target By ~15%

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.